Metabolic Modulators in Angina

1. Introduction/Overview

Brief Introduction to the Topic

Angina pectoris, a clinical manifestation of myocardial ischemia, remains a leading cause of morbidity worldwide. Traditional antianginal therapies primarily focus on vasodilation, reduction of myocardial oxygen demand, and antiarrhythmic actions. In recent decades, attention has shifted toward metabolic modulators, pharmacologic agents that alter myocardial substrate utilization to improve the efficiency of oxygen consumption. By promoting glucose oxidation over fatty acid oxidation or by modulating intracellular ion currents, these agents aim to reduce ischemic injury without affecting coronary perfusion directly.

Clinical Relevance and Importance

Despite advances in revascularization techniques, a substantial subset of patients continues to experience refractory angina. Metabolic modulators offer a therapeutic niche, particularly for patients who are intolerant to conventional antianginals or in whom revascularization is infeasible. Their unique mechanisms of action complement existing therapies, and evidence suggests additive benefits when combined with beta‑blockers or nitrates. Consequently, a thorough understanding of these agents is essential for clinicians and pharmacists involved in cardiovascular care.

Learning Objectives

• Describe the pharmacologic rationale for targeting myocardial metabolism in angina management.
• Identify and classify the principal metabolic modulators currently utilized in clinical practice.
• Explain the mechanisms of action, including relevant ion channel interactions and metabolic pathways.
• Summarize the pharmacokinetic profiles and dosing considerations for ranolazine, trimetazidine, and dichloroacetate.
• Recognize the spectrum of adverse effects, drug interactions, and special population considerations associated with these agents.

2. Classification

Drug Classes and Categories

Metabolic modulators for angina are grouped based on their primary pharmacologic targets:

• Late Sodium Current Inhibitors – e.g., ranolazine.
• Fatty Acid Oxidation Inhibitors – e.g., trimetazidine.
• Pyruvate Dehydrogenase Kinase Inhibitors – e.g., dichloroacetate.

Chemical Classification

Ranolazine is a dihydropyridine derivative lacking calcium‑channel blocking activity. Trimetazidine is a 2,4‑dimethyl‑3‑(2‑hydroxy‑3‑methylpropyl)‐2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑2‑(3‑methyl‑2‑(3‑hydroxy‑… 

Trimetazidine Chemistry

Trimetazidine is a 5‑hydroxylated, 3‑methyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑2‑(3‑hydroxyl‑… 

Dichloroacetate Chemistry

Dichloroacetate (DCA) is a small, halogenated carboxylic acid that functions as a metabolic modulator by inhibiting pyruvate dehydrogenase kinase. Its simplicity facilitates rapid absorption and distribution.

3. Mechanism of Action

Ranolazine (Late Sodium Current Inhibitor)

Ranolazine selectively blocks the late component of the inward sodium current (I_Na,late) in cardiac myocytes. By reducing sustained intracellular sodium accumulation, the drug indirectly lowers intracellular calcium via the Na⁺/Ca²⁺ exchanger. The resultant decrease in diastolic tension and oxygen consumption leads to improved myocardial efficiency, particularly under ischemic conditions. Additionally, ranolazine modestly inhibits the hERG potassium channel, contributing to its potential for QT interval prolongation.

Trimetazidine (Fatty Acid Oxidation Inhibitor)

Trimetazidine exerts its antianginal effect by partially inhibiting the mitochondrial enzyme 3‑ketoacyl‑CoA thiolase, a key step in β‑oxidation of fatty acids. This inhibition shifts substrate utilization toward glucose oxidation, which yields more ATP per oxygen molecule consumed (higher P/O ratio). The metabolic switch reduces myocardial oxygen demand and improves coronary perfusion during ischemic episodes. Trimetazidine also stabilizes cell membranes and may attenuate oxidative stress, although these mechanisms remain less well characterized.

Dichloroacetate (Pyruvate Dehydrogenase Kinase Inhibitor)

Dichloroacetate activates the pyruvate dehydrogenase complex (PDH) by inhibiting pyruvate dehydrogenase kinase (PDK). Enhanced PDH activity increases the conversion of pyruvate to acetyl‑CoA, thereby promoting glucose oxidation and decreasing lactate production. By favoring a more oxygen‑efficient metabolic pathway, DCA reduces lactate accumulation and improves myocardial energy status in ischemic myocardium. Chronic DCA therapy has also been explored for its potential to attenuate mitochondrial dysfunction in metabolic disorders.

4. Pharmacokinetics

Ranolazine

Absorption: Oral bioavailability is approximately 60 % and is minimally affected by food. Peak plasma concentrations are reached within 3–4 h. Distribution: The drug exhibits a large volume of distribution (∼20 L/kg) and binds extensively to plasma proteins (>90 %). Metabolism: Ranolazine is primarily metabolized by CYP3A4 and to a lesser extent by CYP2D6; its major metabolites are inactive. Excretion: Renal elimination accounts for ∼30 % of the dose, with the remainder excreted in feces. Half‑life: The terminal half‑life is 9–13 h, permitting twice‑daily dosing. Dose adjustments are recommended in severe hepatic impairment and when co‑administered with potent CYP3A4 inhibitors or inducers.

Trimetazidine

Absorption: Oral bioavailability is high (∼90 %) with peak concentrations achieved within 1–3 h. Distribution: Trimetazidine is moderately protein‑bound (~30 %) and exhibits a moderate volume of distribution (~1.5 L/kg). Metabolism: The drug undergoes hepatic conjugation via glucuronidation; the metabolites lack significant pharmacologic activity. Excretion: Renal clearance dominates, with 60–70 % of the dose eliminated unchanged. Half‑life: The terminal half‑life is 8–10 h, allowing twice‑daily administration. Dose modifications are unnecessary in mild to moderate renal impairment but may be required in severe dysfunction.

Dichloroacetate

Absorption: DCA is well absorbed orally, with peak plasma levels reached within 30–60 min. Distribution: The drug distributes widely across tissues, achieving measurable concentrations in the myocardium. Metabolism: DCA is metabolized primarily by hepatic aldehyde oxidase, producing dichloroacetyl‑glucuronide and other conjugates. Excretion: Renal clearance accounts for the majority of elimination; the drug and its metabolites are excreted unchanged in urine. Half‑life: Depending on the dose, the half‑life ranges from 1.5 to 3 h; higher doses may exhibit saturation kinetics. Dose adjustments are advised in patients with hepatic impairment or severe renal dysfunction due to altered clearance.

5. Therapeutic Uses/Clinical Applications

Ranolazine

Approved Indication: Chronic stable angina refractory to first‑line therapy or unsuitable for revascularization. The drug is typically added to standard antianginal regimens to reduce anginal episodes and improve exercise tolerance. Off‑Label Uses: In some jurisdictions, ranolazine is prescribed for refractory variant angina or for patients with angina associated with heart failure, although robust evidence remains limited.

Trimetazidine

Approved Indication: Chronic angina pectoris, particularly in patients who cannot tolerate nitrates or β‑blockers. Trimetazidine is often employed as an adjunct to standard therapy and has demonstrated reductions in anginal frequency and nitroglycerin use. Off‑Label Uses: Trimetazidine has been investigated for diabetic neuropathy and chronic fatigue syndrome, with modest efficacy reported in small studies, but routine clinical use in these conditions is not established.

Dichloroacetate

Approved Indication: None in the United States; however, DCA has been approved in several European countries for the treatment of lactic acidosis secondary to mitochondrial disorders. Clinical Trials: In cardiovascular research, DCA has been evaluated for its ability to reduce myocardial ischemia/reperfusion injury and improve left ventricular function post‑myocardial infarction. Nonetheless, its use remains investigational in the context of angina management.

6. Adverse Effects

Ranolazine

• Common: Gastrointestinal disturbances (nausea, diarrhea), dizziness, headache, edema, and mild QT interval prolongation.
• Serious: Arrhythmias, notably torsades de pointes in patients with pre‑existing QT prolongation or electrolyte abnormalities.
• Black Box Warning: Potential for serious ventricular tachyarrhythmias; caution advised in patients with a history of arrhythmias or in combination with other QT‑prolonging agents.

Trimetazidine

• Common: Pruritus, skin rash, diarrhea, and mild nausea.
• Serious: Rare cases of Parkinsonian motor disorders, sialadenitis, and skin disorders such as lichenoid lesions.
• Black Box Warning: Not applicable; however, clinicians should monitor for extrapyramidal symptoms in patients with a predisposition to neurotoxicity.

Dichloroacetate

• Common: Nausea, vomiting, abdominal pain, and transient hyperbilirubinemia.
• Serious: Peripheral neuropathy, hepatotoxicity, and neuropsychiatric disturbances (e.g., anxiety, depression) have been reported, especially with high or prolonged dosing.
• Black Box Warning: None formally issued; nevertheless, caution is advised in patients with pre‑existing hepatic or neurologic disease.

7. Drug Interactions

Ranolazine

• CYP3A4 inhibitors (ketoconazole, clarithromycin) increase ranolazine exposure, raising the risk of QT prolongation.
• CYP3A4 inducers (rifampin, carbamazepine) reduce plasma concentrations and may diminish efficacy.
• Concomitant use with other QT‑prolonging agents (e.g., amiodarone, sotalol) necessitates cardiac monitoring.
• Contraindicated with strong CYP3A4 inhibitors when the cumulative effect on QT interval is uncertain.

Trimetazidine

• Antifungal agents (itraconazole, fluconazole) may elevate trimetazidine levels, though clinical significance is minimal.
• Co‑administration with antiepileptics (phenobarbital, phenytoin) could potentially increase hepatic metabolism.
• Trimetazidine does not significantly interact with major drug transporters or enzymes, limiting interaction potential.

Dichloroacetate

• Strong CYP agents have limited influence on DCA metabolism; however, drugs affecting aldehyde oxidase (e.g., allopurinol) may alter clearance.
• Co‑administration with hepatotoxic medications (e.g., acetaminophen, isoniazid) may compound hepatic burden.
• Interactions with neuroactive drugs (e.g., benzodiazepines) may potentiate neuropsychiatric side effects.

8. Special Considerations

Pregnancy and Lactation

Ranolazine and trimetazidine have limited data in pregnancy; thus, they are generally avoided unless benefits outweigh risks. DCA, lacking extensive reproductive safety data, should also be used with caution. Lactation: All agents are excreted into breast milk at low levels; however, clinical monitoring is advised if lactation continues.

Pediatric Considerations

Current evidence supports ranolazine use in adolescents with refractory angina, but dosing requires careful titration. Trimetazidine is not routinely prescribed in children due to insufficient safety data. DCA has not been studied extensively in pediatric populations; its use remains experimental.

Geriatric Considerations

Age‑associated changes in hepatic and renal function may reduce clearance of all metabolic modulators. Dose adjustments are usually unnecessary for ranolazine and trimetazidine in mild to moderate renal impairment, but vigilant monitoring for adverse effects, particularly QT prolongation, is warranted. For DCA, caution is advised due to potential neurotoxicity and hepatic metabolism.

Renal and Hepatic Impairment

Ranolazine: Mild to moderate renal impairment does not require dose modification; severe impairment may necessitate dose reduction or avoidance. Trimetazidine: Renal dysfunction (eGFR <30 mL/min) recommends dose reduction to 5 mg BID. DCA: Hepatic dysfunction leads to accumulation of the drug; dosing should be reduced or therapy discontinued if hepatic enzymes exceed three times the upper limit of normal.

9. Summary/Key Points

• Metabolic modulators represent a distinct therapeutic class that improves myocardial efficiency by shifting substrate utilization from fatty acids to glucose.
• Ranolazine selectively inhibits late sodium current, reducing intracellular calcium overload and oxygen demand.
• Trimetazidine partially blocks fatty acid β‑oxidation, favoring glucose oxidation with a higher ATP yield per oxygen molecule.
• Dichloroacetate activates pyruvate dehydrogenase, enhancing glucose oxidation and mitigating lactate accumulation.
• Clinical advantages include reduction of anginal episodes and improved exercise tolerance, particularly in patients intolerant to conventional antianginals.
• Adverse effect profiles vary: ranolazine carries a risk of QT prolongation; trimetazidine may cause extrapyramidal symptoms; DCA is associated with neurotoxicity at high doses.
• Drug interactions largely involve metabolism via CYP3A4; caution is advised when combining with other QT‑prolonging agents.
• Special populations—pregnancy, lactation, pediatrics, geriatrics, and patients with organ impairment—require individualized dosing and monitoring strategies.
• Ongoing research explores the role of DCA and other novel modulators in ischemic heart disease, indicating potential for future therapeutic expansion.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.